Mo1884 Prevalence of Inflammatory Bowel Disease Among Patients With Psoriasis and Incidence of Serious Infections in This Subset: Results From the PSOLAR Registry

Ustekinumab in treatment of Crohn’s disease: design, development, and potential place in therapy

“…The cumulative incidence rates of SIs (within 91 days of biologic administration) have also been evaluated among patients with self-reported IBD in the PSOLAR registry 56. The cumulative incidence rates of SI (per 100 patient years) for patients with IBD were higher than the total PSOLAR population (1.38 vs 0.93) for ustekinumab exposure.…”

Ustekinumab in the management of Crohn’s disease: Expert opinion

“…Overall, data from the PSOLAR registry confirm the safety of ustekinumab in a 'real-life' scenario and when compared with other biological agents. Ustekinumab was associated with the lowest rate of serious infection per 100 patient-years of all biological therapies recorded in the PSOLAR registry [59].…”

A Practical Guide to the Safety and Monitoring of New IBD Therapies

“…Similarly, in randomized clinical trials, ustekinumab demonstrated no increased infection frequency compared with placebo (2.3% vs 2.3%) 20 and the Psoriasis Longitudinal Assessment and Registry (PSOLAR), which monitors ustekinumab for psoriasis, demonstrated an infection rate of 1.3 per 100 person years (PY) with ustekinumab compared with 5.75 per 100 with infliximab. 21 Furthermore, there is a lower rate of TB reactivation with ustekinumab than anti-TNF (0.02 per 100 person years; infliximab 0.39; golilumab 0.24). In the UNITI trials of ustekinumab for Crohn's disease, there was one subject that developed listeria meningitis and one subject that contracted an ophthalmic herpes infection.…”